With the SARS-CoV-2 Inhibition by Hybrid Graphene Nanoplatelet/Metal Oxide Powders announcement, Share Talk spoke with CEO, Neill Ricketts.
Versarien Plc (AIM: VRS), the advanced materials engineering group, announced the receipt of an independent report (the “Report”) produced by Ankara University, Turkey, detailing the results of a preliminary study of modified graphene materials provided by Versarien for use against SARS-CoV-2, the strain of coronavirus that causes coronavirus disease 2019, COVID-19.
The Report concludes that the preliminary test results show that these materials significantly inhibit viral infection and possess anti-viral activity towards SARS-CoV-2.
Neill Ricketts, CEO of Versarien, commented: “While we must stress that these results have been achieved under laboratory conditions, they do demonstrate that our hybrid graphene nanomaterials have the potential to provide protection from COVID-19.
The results provide us with sufficient levels of confidence for our combined Gnanomat and 2-DTech teams to move to rapid testing of these materials in real-world applications as diverse as face masks, clothing and surface treatments, together with investigating the protection that they can provide from other viruses and bacteria.
“I would like to thank Dr Yilmazer Aktuna and her team at Ankara University for the work they have undertaken. We will continue to work with them on further projects to investigate the anti-viral properties of our materials and their applications.”
